# EDGAR Filing Document

**Accession Number:** 0001454789
**File Stem:** 0001140361-26-002222
**Filing Date:** 2026-1
**Character Count:** 10175
**Document Hash:** 75668ae7c041f8dca4a79f87ed7f0486
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001140361-26-002222.hdr.sgml**: 20260123

**ACCESSION NUMBER**: 0001140361-26-002222

**CONFORMED SUBMISSION TYPE**: S-8 POS

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20260123

**DATE AS OF CHANGE**: 20260123

**EFFECTIVENESS DATE**: 20260123

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Astria Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001454789
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8 POS
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-206394
- **FILM NUMBER:** 26557123

**BUSINESS ADDRESS:**
- **STREET 1:** 22 BOSTON WHARF ROAD
- **STREET 2:** 10TH FLOOR
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02210
- **BUSINESS PHONE:** 617-349-1971

**MAIL ADDRESS:**
- **STREET 1:** 22 BOSTON WHARF ROAD
- **STREET 2:** 10TH FLOOR
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02210

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CATABASIS PHARMACEUTICALS INC
- **DATE OF NAME CHANGE:** 20090127

#### As filed with the Securities and Exchange Commission on January 23, 2026.

#### Registration No. 333-206394

#### Registration No. 333-210229

#### Registration No. 333-216793

#### Registration No. 333-223721

#### Registration No. 333-229643

#### Registration No. 333-239114

#### Registration No. 333-254151

#### Registration No. 333-258633

#### Registration No. 333-263459

#### Registration No. 333- 273773

#### Registration No. 333-281491
**Registration No. 333-289533**<br>

**** 

<br> ------

### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

#### Washington, D.C. 20549

#### Post-Effective Amendment No. 1 to Registration Statement No. 333-206394

#### Post-Effective Amendment No. 1 to Registration Statement No. 333-210229

#### Post-Effective Amendment No. 1 to Registration Statement No. 333-216793

#### Post-Effective Amendment No. 1 to Registration Statement No. 333-223721

#### Post-Effective Amendment No. 1 to Registration Statement No. 333-229643

#### Post-Effective Amendment No. 1 to Registration Statement No. 333-239114

#### Post-Effective Amendment No. 1 to Registration Statement No. 333-254151

#### Post-Effective Amendment No. 1 to Registration Statement No. 333-258633

#### Post-Effective Amendment No. 1 to Registration Statement No. 333-263459

#### Post-Effective Amendment No. 1 to Registration Statement No. 333-273773

#### Post-Effective Amendment No. 1 to Registration Statement No. 333-281491

#### Post-Effective Amendment No. 1 to Registration Statement No. 333-289533

#### to

#### <br>

### FORM S-8

#### REGISTRATION STATEMENT

#### UNDER THE SECURITIES ACT OF 1933

## ASTRIA THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)

---

| | |
|:---|:---|
| **Delaware**<br> (State or other jurisdiction of incorporation or organization) | **26-3687168**<br> (I.R.S. Employer Identification No.) |
| **22 Boston Wharf Road**<br> **10<sup>th</sup> Floor**<br> **Boston, Massachusetts**<br> (Address of Principal Executive Offices) | **02210**<br> (Zip Code) |

---

#### Amended and Restated 2008 Equity Incentive Plan, as amended

#### 2015 Stock Incentive Plan

#### 2015 Employee Stock Purchase Plan

#### Amended and Restated 2015 Stock Incentive Plan

#### Quellis Biosciences, Inc. 2019 Stock Incentive Plan

#### 2022 Inducement Stock Incentive Plan

#### 2022 Inducement Stock Incentive Plan, as amended

#### Second Amended and Restated 2015 Stock Incentive Plan, as amended
(Full title of the plans)

#### Alane Barnes

#### Secretary

#### Astria Therapeutics, Inc.

#### 4505 Emperor Blvd., Suite 200

#### Durham, North Carolina 27703
(Name and address of agent for service)

(919) 859-1302

(Telephone number, including area code, of agent for service)

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐ Accelerated filer ☐ <br> Non-accelerated filer ☒ Smaller reporting company ☒ <br> Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

------

#### DEREGISTRATION OF SECURITIES
This Post-Effective Amendment (the "Post-Effective Amendment") relates to the following Registration Statements on Form S-8 (each, a "Registration Statement" and together, the "Registration Statements"):

• Registration Statement on Form S-8 (No. 333-206394), pertaining to the registration and sale of (i) 1,478,731 shares of common stock of Astria Therapeutics, Inc. (the "Company"), $0.001 par value per share ("Common Stock"), in connection with the Amended and Restated 2008 Equity Incentive Plan, as amended, (ii) 1,094,229 shares of Common Stock in connection with the 2015 Stock Incentive Plan, and (iii) 182,352 shares of Common Stock in connection with the 2015 Employee Stock Purchase Plan;

<br> • Registration Statement on Form S-8 (No. 333-210229), pertaining to the registration and sale of 765,663 shares of Common Stock in connection with the 2015 Stock Incentive Plan and 2015 Employee Stock Purchase Plan;

<br> • Registration Statement on Form S-8 (No. 333-216793), pertaining to the registration and sale of 940,877 shares of Common Stock in connection with the 2015 Stock Incentive Plan and 2015 Employee Stock Purchase Plan;

<br> • Registration Statement on Form S-8 (No. 333-223721), pertaining to the registration and sale of 1,182,262 shares of Common Stock in connection with the 2015 Stock Incentive Plan and 2015 Employee Stock Purchase Plan;.

<br> • Registration Statement on Form S-8 (No. 333-229643), pertaining to the registration and sale of 886,470 shares of Common Stock in connection with the Amended and Restated 2015 Stock Incentive Plan and 2015 Employee Stock Purchase Plan;

<br> • Registration Statement on Form S-8 (No. 333-239114), pertaining to the registration and sale of 2,036,470 shares of Common Stock in connection with the Amended and Restated 2015 Stock Incentive Plan and 2015 Employee Stock Purchase Plan;

<br> • Registration Statement on Form S-8 (No. 333-254151), pertaining to the registration and sale of 332,494 shares of Common Stock in connection with the Quellis Biosciences, Inc. 2019 Stock Incentive Plan;

<br> • Registration Statement on Form S-8 (No. 333-258633), pertaining to the registration and sale of 6,036,470 shares of Common Stock in connection with the Amended and Restated 2015 Stock Incentive Plan and 2015 Employee Stock Purchase Plan;

<br> • Registration Statement on Form S-8 (No. 333-263459), pertaining to the registration and sale of 300,000 shares of Common Stock in connection with the 2022 Inducement Stock Incentive Plan;

• Registration Statement on Form S-8 (No. 333-273773), pertaining to the registration and sale of additional shares of Common Stock in connection with the Amended and Restated 2015 Stock Incentive Plan, the 2015 Employee Stock Purchase Plan and the 2022 Inducement Stock Incentive Plan;

• Registration Statement on Form S-8 (No. 333-281491), pertaining to the registration and sale of additional shares of Common Stock in connection with the Second Amended and Restated 2015 Stock Incentive Plan, the 2015 Employee Stock Purchase Plan and the 2022 Inducement Stock Incentive Plan, as amended; and

• Registration Statement on Form S-8 (No. 333-289533), pertaining to the registration and sale of additional shares of Common Stock in connection with the Second Amended and Restated 2015 Stock Incentive Plan, as amended, the 2015 Employee Stock Purchase Plan and the 2022 Inducement Stock Incentive Plan, as amended.

On January 23, 2026, pursuant to the Agreement and Plan of Merger, dated as of October 14, 2025, by and between BioCryst Pharmaceuticals, Inc., a Delaware corporation ("BioCryst"), Axel Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BioCryst ("Merger Sub"), and the Company, Merger Sub was merged with and into the Company (the "Merger"), with the Company surviving as a wholly owned subsidiary of BioCryst.

As a result of the Merger, the offering and sale of securities under the above-listed Registration Statements under the Securities Act of 1933, as amended, which have been previously filed with the Securities and Exchange Commission, have been terminated. In accordance with the undertakings made by the Company in the Registration Statements to remove from registration by means of a post-effective amendment any of the securities that remain unsold at the termination of the offering, the Company hereby terminates the effectiveness of the Registration Statements and removes from registration the securities of the Company registered but unsold under the Registration Statements as of the date hereof. The Registration Statements are hereby amended, as appropriate, to reflect the deregistration of such securities.

------

#### SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Post-Effective Amendment to the Registration Statements to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Durham, State of North Carolina on January 23, 2026.

---

| | |
|:---|:---|
| **ASTRIA THERAPEUTICS, INC.** | **ASTRIA THERAPEUTICS, INC.** |
| By: | /s/ Alane Barnes |
|  | Alane Barnes |
|  | Secretary |

---

No other person is required to sign this Post-Effective Amendment to each Registration Statement in reliance upon Rule 478 under the Securities Act of 1933, as amended.

------